252 related articles for article (PubMed ID: 27341413)
1. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
[TBL] [Abstract][Full Text] [Related]
2. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.
Rosario PW; Mourão GF; Calsolari MR
Clin Endocrinol (Oxf); 2016 Sep; 85(3):453-8. PubMed ID: 26801644
[TBL] [Abstract][Full Text] [Related]
3. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
Mourão GF; Rosario PW; Calsolari MR
Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Oct; 37(10):1024-9. PubMed ID: 27306852
[TBL] [Abstract][Full Text] [Related]
5. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
6. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
7. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
8. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
10. Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.
Rosario PW; Mourão G; Calsolari MR
J Endocrinol Invest; 2019 Jun; 42(6):687-692. PubMed ID: 30353424
[TBL] [Abstract][Full Text] [Related]
11. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?
Rosario PW; Mourão GF; Calsolari MR
Endocrine; 2020 Dec; 70(3):552-557. PubMed ID: 32653994
[TBL] [Abstract][Full Text] [Related]
12. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
14. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
15. A low postoperative nonstimulated serum thyroglobulin level excludes the presence of persistent disease in low-risk papillary thyroid cancer patients: implication for radioiodine indication.
Rosario PW; Mourão GF; Siman TL; Calsolari MR
Clin Endocrinol (Oxf); 2015 Dec; 83(6):957-61. PubMed ID: 25393656
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
17. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
18. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
Furtado Mde S; Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?
Wong H; Wong KP; Yau T; Tang V; Leung R; Chiu J; Lang BH
Ann Surg Oncol; 2012 Oct; 19(11):3479-85. PubMed ID: 22576067
[TBL] [Abstract][Full Text] [Related]
20. A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.
Robenshtok E; Grewal RK; Fish S; Sabra M; Tuttle RM
Thyroid; 2013 Apr; 23(4):436-42. PubMed ID: 23067402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
